ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      60,182.33
      1.60%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Lexicon Pharmaceuticals Inc (LXRX)

      7. Lexicon Pharmaceuticals Inc (LXRX) News

      LXRX

      Lexicon Pharmaceuticals (LXRX)

      Lexicon Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:LXRX
      DateTimeSourceHeadlineSymbolCompany
      06/12/20184:39PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/07/20187:39PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/04/20185:33PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/04/20186:32AMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/25/20184:46PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/24/20187:00AMGlobeNewswire Inc.Lexicon Pharmaceuticals to Present at Upcoming Investor ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/22/20188:03AMGlobeNewswire Inc.FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/22/20188:01AMPR Newswire (US)FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/04/20188:00AMGlobeNewswire Inc.Lexicon Pharmaceuticals Announces Publication of New XERMELO® (Telotristat Ethyl) Data in Clinical TherapeuticsNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/03/20185:24PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/03/20187:15AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/03/20187:00AMGlobeNewswire Inc.Lexicon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides a Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/02/20189:18AMGlobeNewswire Inc.Lexicon Pharmaceuticals to Present at Upcoming Investor ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/27/20185:52PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/27/20185:52PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/27/20185:51PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/27/20185:51PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/27/20185:51PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/27/20185:51PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/27/20185:51PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/27/20185:50PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/26/20185:12PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/26/20187:00AMGlobeNewswire Inc.Lexicon Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on May 3, 2018NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/23/20185:17PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      04/03/20187:00AMGlobeNewswire Inc.Lexicon Pharmaceuticals to Highlight Pipeline Progress at R&d Day on April 10, 2018NASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/29/20181:00AMGlobeNewswire Inc.Lexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application (MAA) for Sotagliflozin to Treat Adul...NASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/26/20187:00AMGlobeNewswire Inc.Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults With Type 1 DiabetesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/16/20187:11AMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/16/20187:07AMEdgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      03/02/20185:21PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:LXRX